EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, published by SAGE PUBLICATIONS INC, is a premier academic journal dedicated to advancing the understanding of mental health issues and neurological disorders in the aging population. With an established presence since 1988, this journal stands out in the fields of Geriatrics, Gerontology, Neurology, and Psychiatry, currently positioned in the Q2 category based on 2023 metrics, reflecting its influence and academic rigor. The journal is indexed in major databases and is highly regarded for its contributions, as evidenced by its strong Scopus rankings. It serves as an essential resource for researchers, clinicians, and students, offering insightful articles that explore the complex interplay between aging, mental health, and neurological conditions. Although it does not provide open access, it continues to be a vital source of scholarly knowledge for those dedicated to enhancing the well-being of the elderly population.

Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE is a pivotal journal in the fields of neurology, psychiatry, and related medical disciplines, published by GEORG THIEME VERLAG KG in Germany. With a history dating back to 1955, this journal has evolved to address the dynamic nature of neurological and psychiatric research, offering valuable insights and advancements in the field. Despite holding a Q4 category status in various medical domains according to the 2023 quartiles, the journal continues to foster academic discussion and engagement among researchers and clinicians alike. It serves as a vital platform for disseminating knowledge through original research articles, reviews, and clinical studies, making it an essential resource for professionals and students aiming to stay abreast of the latest developments in mental health and neurological science. Although the journal currently does not offer open access options, its contribution to the academic community is significant, helping to illuminate the intricate relationships between neurological disorders and psychiatric conditions.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

SEMINARS IN NEUROLOGY is a leading journal in the field of neurology, published by THIEME MEDICAL PUBL INC. With its ISSN 0271-8235 and E-ISSN 1098-9021, this esteemed journal has been a vital resource for the neurology community since its inception in 1984. Covering critical advancements and contemporary issues in both neurology and clinical neurology, it holds a reputable position in the Q2 category for both disciplines as of 2023. The journal ranks #164 out of 400 in clinical neurology, indicating its significant contribution to the field, and is indexed in Scopus for robust academic exposure. SEMINARS IN NEUROLOGY offers a platform for authors to disseminate groundbreaking research and reviews, ultimately enhancing knowledge and practice in neurological sciences. With unrestricted access options, it seeks to engage researchers, practitioners, and students, fostering a comprehensive understanding of the complexities of neurological disorders and therapies.

Neurology International is a prestigious open-access journal published by MDPI that has been making significant contributions to the field of neurology since its establishment in 2009. With its ISSN 2035-8377, this journal is committed to disseminating high-quality, peer-reviewed research that addresses a wide range of clinical topics in neurology. Operating out of Basel, Switzerland, the journal holds a respectable Q2 ranking in the clinical neurology category as of 2023, indicating its influence and dedication to advancing scientific knowledge. Researchers and practitioners alike will find value in its comprehensive articles, which are readily accessible to a global audience, facilitating the sharing of innovative findings and clinical practices. As it converges towards 2024, Neurology International continues to provide a vital platform for scholarly discourse, aiming to improve patient outcomes and enhance our understanding of neurological disorders.

The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

Current Treatment Options in Neurology, published by CURRENT MEDICINE GROUP, is a pivotal journal in the field of clinical neurology, dedicated to enhancing the understanding and management of neurological disorders. With a print ISSN of 1092-8480 and an E-ISSN of 1534-3138, this journal serves as a vital resource for clinicians, researchers, and students alike, providing evidence-based insights and treatment strategies from its continuous publication since its inception in 1999. It currently holds a respectable rank in the Q3 quartile, reflecting its competitive standing in the Scopus rankings for clinical neurology, placing it at the 51st percentile. Although not classified as Open Access, the journal continues to provide valuable contributions that inform clinical practices and improve patient outcomes in neurological care. With its comprehensive reviews and clinical focus, Current Treatment Options in Neurology remains an essential platform for disseminating the latest advancements in treatment methodologies and therapeutic options, solidifying its importance in the ever-evolving landscape of neurology.